A Phase 1, Randomized, Double-blind, Placebo-controlled, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 04 Jan 2017
At a glance
- Drugs Revusiran (Primary)
- Indications Amyloidosis; Cardiomyopathies
- Focus Adverse reactions
- Sponsors Alnylam Pharmaceuticals
- 04 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 21 May 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 25 Feb 2015 Planned number of patients changed from 76 to 96, according to ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History